Discussion
T2DM, diabetes
EVENTS, DIABETES
The multicenter clinical study showed that in T2DM patients inadequately controlled with diet and exercise intervention, fotagliptin 12 mg once daily for 24 weeks provided superior glycemic control compared with placebo, as assessed by reductions in HbA1c and FBG. No clinically significant difference in the improvements in clinical response of glycemic control was observed between the fotagliptin group and the alogliptin group.HbA1c represents the most powerful predictor of diabetes related outcomes and mortality [Fotagliptin is a novel highly selective DPP-4 inhibitor under clinical development for the increased levels of intact bioactive GIP and GLP-1. Based on previous studies, fotagliptin could increase active GLP-1 concentrations and have no obvious influence on DPP-8 and DPP-9, thus making it safer to treat T2DM [However, limitations existed in the present trial. First of all, there is a potential limitation in interpreting effect of fotagliptin compared with placebo on risk of major cardiovascular (CV) events, as the study duration may be too short to modulate CV related clinical outcomes. Four previous CV outcome trials of DPP-4 inhibitors have demonstrated a non-inferior risk of a composite CV outcome when compared with placebo [